New Aspirin Test Now Available Through Diagnostic Laboratory Medicine

May 11, 2011

For Immediate Release

New Aspirin Test Now Available Through Diagnostic Laboratory Medicine

AspirinWorks® Test from Corgenix Medical tells doctors, patients if aspirin therapy is working to reduce their risk of heart attack or stroke

BEDFORD, Mass. — May 11, 2011 — A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks® Test (www.aspirinworks.com) is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine (www.dlmlabs.com).

Dr. Joseph Musto, President and Medical Director of Diagnostic Laboratory Medicine, said the AspirinWorks Test is an important addition to the laboratory’s testing services.

“We’re pleased to be one of the first clinical laboratories in the region to offer this valuable test,” said Dr. Musto. “AspirinWorks represents a simple, non-invasive, reliable test for physicians who realize that patients may respond differently to different doses of aspirin. This test truly helps physicians understand their patients’ health on a personal level.”

Aspirin, taken by millions of Americans every day to reduce the risk of heart attack and stroke, works by making blood platelets less sticky and thus less likely to form a blood clot. Major clinical studies have shown that as many as one in four patients are not adequately protected by their aspirin therapy.

The AspirinWorks Test, developed by Corgenix Medical Corp. (OTCQB: CONX.PK), determines the effect of aspirin on platelets by measuring the level of the biomarker called thromboxane B2. The higher the levels of thromboxane B2, the stickier the blood platelets and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient’s therapy, which may be as simple as adjusting the dose.

AspirinWorks is the only FDA-cleared test that measures urinary thromboxane B2 to accurately determine aspirin effect in apparently healthy individuals. Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained at the doctor’s office.

The AspirinWorks Test is reimbursed by most insurance carriers and covered under Medicare. Physicians interested in ordering the test can contact Diagnostic Laboratory Medicine at 1-800- 582-6248 or visit www.dlmlabs.com.

About Diagnostic Laboratory Medicine

Diagnostic Laboratory Medicine (DLM) is a full-service medical laboratory headquartered in Bedford, Mass., with convenient satellite Patient Service Centers located throughout eastern Massachusetts. DLM staff have been exceeding client expectations for more than 30 years, and each specimen is treated as a patient, not a number. DLM’s headquarters location houses multiple departments, providing technical, sales and billing support under one roof. More information is available at www.dlmlabs.com or by calling 800-582-6248 and asking to speak with Dr. Joseph Musto directly.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com